MedTrace Logo

Analysis on the Infection Risk, Prognosis, and Drug Sensitivity of Klebsiella Pneumoniae.

NCT04337840 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-05-07

No results posted yet for this study

Summary

Nosocomial infections are increasing rapidly both internationally and domestically, especially carbapenem-resistant Klebsiella pneumoniae infections. However, there were still lack of evidence about the risk and prognosis in Taiwan. The choice of drug and related sensitivity test was also limited. We would analyze the infection risk, prognosis, and drug sensitivity of Klebsiella pneumoniae and focus on strategy to manage carbapenem-resistant Klebsiella pneumoniae infections.

Conditions

  • Klebsiella Pneumoniae Sepsis

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yu-Chung Chuang · National Taiwan University Hospital

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-05
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04337840 on ClinicalTrials.gov